 This is a randomized, controlled trial that will test the hypothesis that replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy IRMTwill improve freedom from failure FFF relative to 80 Gy IMRT alone in patients with newly-diagnosed prostate cancer with an intermediate-risk profile. 